Sinopharm Holding (Tianjin) Medical Devices Co., Ltd. provides the national and international high-quality medical device equipment for all levels of hospitals in Tianjin, involving medical equipment, common consumables, reagents, orthopedics products, surgical instruments, high-value consumables in cardiovascular, cerebrovascular and nervous system, supply chain management system software, etc. Most products are sold by provincial agents. Quite a number of products are national and foreign famous brands.
Depending on 33,000m2 modern logistics warehouse in Sinopharm Logistics, the daily treatment of Sinopharm Holding (Tianjin) Medical Devices Co., Ltd. may reach 3,5000 pieces through automated sorting and professional transportation.
The warehouse may conduct real-time monitoring on the storage and operation through electronic labeling system, LED control system, 3D warehouse monitoring computer, 3D warehouse scheduling system, WMS (Warehouse Management System), WCS (Warehouse Control System), monitoring system of conveying line and sorting machine, temperature and humidity monitoring system, access control system, monitoring record system, etc.
WMS system is the software of MANH, which has been widely applied in the logistics centers of over 300 subsidiaries subordinate to Sinopharm. The stability and effectiveness have been sufficiently approved by other districts and industries. Through the professional warehouse management system, the company may achieve order treatment and data analysis for the logistics business of medical instrument manufacturers, truly, completely and accurately record and effectively monitor the full course of quality management. On the basis of guaranteeing information safety and reliability, the company established the commodity information platform, and built information contact with the suppliers and terminal users through modern communication network technology, barcode technology, electronic data exchange technology. Information management and extension move forward the model of supply chain.
Sinopharm Holding〔Tianjin〕Medical Devices Co., Ltd. establishes the terminal sales network covering the whole Tianjin City, owns the professional product promotion team and abundant channel resources, keeps excellent cooperation relations with the vast users, and provides comprehensive services and technical support for the vast users and business partners. The manufacturers cooperating with our company include Johnson & Johnson, Medtronic, Stryker, Abbott, LEPU, Firebird, Frankenman, Beckman, Roche Group, Beelen, etc. The company is permitted to operate class I, class II and class III medical equipment.
Sinopharm Holding (Tianjin) Medical Devices Co., Ltd. has established long-term cooperation relations with numerous domestic and international well-known equipment manufacturers. At present, the main products include hemoperfusion cartridge, medicine placing machine, medicine dispensing machine, etc.
Currently, Sinopharm Holding (Tianjin) Medical Devices Co., Ltd. has over 400 cooperation units. The company may centrally purchase over 9,000 medical equipment. The products cover the national and international famous manufacturers and brands.
Sinopharm is a medical health industry group with the largest scale, the most complete industry chain and the strongest comprehensive strength in China, which is directly managed by State-owned Assets Supervision and Administration Commission of the State Council. The principal industry is the distribution, retail, R&D and production of products related to the prevention, treatment, diagnosis and care. The company subordinates 10 wholly-owned or holding subsidiaries and 6 listed companies (Sinopharm, Sinopharm Shares, China National Accord Medicines Corporation Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd. and China TCM. In 2005－2015, the annual average growing rate of the business income, gross profits and gross assets was respectively 26.89%, 35.28% and 31.16%. In 2015, the group's operating income reached nearly RMB 300 billion. The company became the only Chinese pharmaceutical enterprise ranked the world's top five hundred.